-
Pharma Transparency Policies Are Vague and Contradictory, Analysis Finds Stat by Ed Silverman — After several years in which drugmakers have been pressured to release clinical trial data, a new analysis finds many companies are still doing an incomplete or inconsistent job of being transparent. Overall, 95 percent of the 42 companies reviewed — including the 25 largest drug makers, based on sales — had a publicly accessible policy. Otherwise, however, the specifics often varied wildly in terms of what is disclosed and even how to interpret some of the policies.